- Policy
- The goal shorten the development of mRNA vaccine to 100 days
- by Lee, Hye-Kyung Sep 6, 2022 05:51am
- SK Bioscience, which developed Korea's No. 1 COVID-19 vaccine, aims to shorten the development period of the mRNA vaccine to 100 days and create innovative technology that can be supplied to the world within six months. 1 Choi Chang-won, vice chairman of SK Discovery's CEO, gave a keynote speech at the "2022 Global Bio Conference" held at Gra
- Policy
- Checking the effectiveness of SKYCovione,
- by Kim, Jung-Ju Sep 6, 2022 05:51am
- SKYCovione, South Korea's No. 1 COVID-19 vaccine developed by SK Bioscience, has been confirmed to have an additional vaccination effect in the cross-neutralization of the omicron mutation virus (BA.1, BA.5). Korea National Institute of Health (Director Kwon Joon-wook) announced on the 2nd that it has confirmed cross-neutralizing anti-bibo
- Policy
- Including SKYCovione, 6 types of COVID-19 vaccines
- by Lee, Jeong-Hwan Sep 6, 2022 05:51am
- With the seventh outbreak of COVID-19 expected this winter, the type of COVID-19 vaccine and the age of vaccination are expected to expand ahead of the winter vaccination. Following the previously licensed Pfizer, Moderna, and Janssen vaccines, domestic SK Bioscience vaccines have been approved, and additional vaccines for omicron mutation
- Policy
- Drugs granted conditional approv to report clinical progress
- by Lee, Hye-Kyung Sep 5, 2022 05:55am
- Treatments for life-threatening serious and rare diseases are being granted conditional approval from July 21st this year. However, to inform the public of the conditions, items for which data on confirmatory clinical trials were not submitted should be specified in the label’s indication, and the clinical trial status of the subject drugs
- Policy
- MFDS has launched permission review for Pfizer Comirnaty 2
- by Kim, Jung-Ju Sep 5, 2022 05:55am
- Pfizer's COVID-19 2-valent vaccine Comirnaty2 0.1mg/mL permission review has begun. The Ministry of Food and Drug Safety (Director Oh Yoo-kyung) announced that Pfizer Korea has applied for permission today (29th) to import 0.1mg/mL of Comirnati 2, an mRNA-type bivalent vaccine that expresses the initial COVID-19 virus and mutant virus (Omi
- Policy
- Will Migraine drug Ajovy be reimbursed following Emgality?
- by Lee, Tak-Sun Sep 2, 2022 06:03am
- With the new migraine drug Emgality (galcanezumab, Lilly) being applied reimbursement in Korea starting this month, a green light has been given to Teva-Handok’s new migraine drug as well. The new drug has passed the reimbursement adequacy assessment of the Health Insurance Review and Assessment Service, after which the company will be enter
- Policy
- The MFDS reviews Pfizer's vaccine permission for infants
- by Lee, Hye-Kyung Sep 2, 2022 06:03am
- The Ministry of Food and Drug Safety (Director Oh Yoo-kyung) announced on the 1st that Pfizer Korea has begun reviewing the item as it applied for permission for imported items of the early COVID-19 vaccine for infants (6 months to 4 years old). The efficacy of "Comirnati 0.1mg/mL (for ages 6 months to 4 years)" applied this time is "Preve
- Policy
- Tylenol ER, voluntarily withdrawn, will be maintained
- by Kim, Jung-Ju Sep 2, 2022 06:03am
- Along with the withdrawal of Janssen Korea's Hyangnam plant, the suspension for Tylenol ER 8 hrs and children's Tylenol suspension, which were voluntarily withdrawn due to item maintenance, will be maintained until this year. The insurance drug product code of nursing institutions will continue to be maintained until the end of the year and c
- Policy
- Advance reservations for SKYCovione will begin on the 1st
- by Kim, Jung-Ju Sep 2, 2022 06:02am
- The inoculation of the COVID-19 vaccine SKYCovione developed by SK Bioscience has begun in earnest. Starting with pre-booking tomorrow (1st), day-to-day and door-to-door vaccinations will be started from the 5th. In addition, the COVID-19 bivalent vaccine will be introduced and vaccinated in the fourth quarter of this year. Lee Ki-il, the
- Policy
- MFDS sets next year's budget at ₩669.4 billion
- by Lee, Hye-Kyung Sep 1, 2022 05:56am
- The Ministry of Food and Drug Safety (Minister: Yu-Kyoung Oh) had compiled its budget plan for 2023 at &8361;669.4 billion, a &8361;5.4 billion (0.8%) increase from the &8361;664 billion that had been set for this year. The next year’s budget proposal is focused on the definite implementation of the new administration’s national tasks &
